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Abstract
Background: Annotations of the phylogenetic tree of the human kinome is an intuitive way to visualize compound
profiling data, structural features of kinases or functional relationships within this important class of proteins. The
increasing volume and complexity of kinase-related data underlines the need for a tool that enables complex
queries pertaining to kinase disease involvement and potential therapeutic uses of kinase inhibitors.
Results: Here, we present KinMap, a user-friendly online tool that facilitates the interactive navigation through
kinase knowledge by linking biochemical, structural, and disease association data to the human kinome tree. To this
end, preprocessed data from freely-available sources, such as ChEMBL, the Protein Data Bank, and the Center for
Therapeutic Target Validation platform are integrated into KinMap and can easily be complemented by proprietary
data. The value of KinMap will be exemplarily demonstrated for uncovering new therapeutic indications of known
kinase inhibitors and for prioritizing kinases for drug development efforts.
Conclusion: KinMap represents a new generation of kinome tree viewers which facilitates interactive exploration
of the human kinome. KinMap enables generation of high-quality annotated images of the human kinome tree
as well as exchange of kinome-related data in scientific communications. Furthermore, KinMap supports multiple
input and output formats and recognizes alternative kinase names and links them to a unified naming scheme,
which makes it a useful tool across different disciplines and applications. A web-service of KinMap is freely available
at http://www.kinhub.org/kinmap/.
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Background
Protein kinases are key effectors in the intracellular sig-
nal transduction pathways and, when dysregulated by
mutations or overexpression, can cause the progression
of diseases such as cancer and inflammation [1]. Since
the clinical success of Gleevec (imatinib) in the treat-
ment of chronic myeloid leukemia [2], protein kinases
have become among the most pursued drug targets for
cancer. The human kinome comprises nearly 540 ki-
nases which were initially classified by Manning et al.
based on the underlying sequences into eight typical
groups (AGC, CAMK, CK1, CMGC, STE, TK, TKL,
Other) and 13 atypical families [3]. The resulting phylo-
genetic tree is commonly used to visualize compound pro-
filing data [4, 5] or structural features of kinases [6, 7]. A
continuously growing body of knowledge is available, cov-
ering not only structural and biochemical aspects but also
data related to diseases and genetic modifications. Hence,
a tool that integrates kinome-related data from multiple
resources would allow exploration of complex queries per-
taining to kinase involvement in the pathophysiology of
various disorders as well as to the disease-modulating po-
tential of protein kinase inhibitors. To date, a few kinome
tree viewers have been developed to facilitate visualization
tasks such as the TREEspot tool from DiscoveRx [8], the
NCGC Kinome Viewer [9], and Kinome Render [10]. The
former two were primarily designed for the visualization
of compound profiling data but they do not allow the
annotation of further information in a straightforward
manner. Kinome Render offers a wider variety of annota-
tion formats and customizable text labels, but it requires a
specialized input file format and does not accept input
from commonly used formats such as spreadsheets. More-
over, Kinome Render only creates static images and does
* Correspondence: fulle@bio.mx
1BioMed X Innovation Center, Im Neuenheimer Feld 515, 69120 Heidelberg,
Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Eid et al. BMC Bioinformatics  (2017) 18:16 
DOI 10.1186/s12859-016-1433-7
not allow interactive linking to other kinome-related re-
sources. The mentioned limitations of already existing
kinome tree viewers motivated us to develop KinMap.
KinMapis a web-based tool for creating interactive an-
notations of the phylogenetic tree of the human kinome
and facilitating navigation through kinase-related data
such as the number of available PDB structures, number
of compound data in ChEMBL, inhibitor profiling data
sets, kinase disease associations, as well as proprietary
data. The online tool supports various input and output
formats (e.g. spreadsheets), recognizes alternative kinase
naming schemes and produces high-resolution images.
Finally, KinMap employs modern web technologies to
run entirely locally in the web browser without upload-
ing sensitive data to a server. The key features of Kin-
Map are summarized in Fig. 1a and discussed in detail
below.
Implementation
Kinome navigation via precompiled data sources
To facilitate the exploration of kinase-related information,
structural, biochemical, and functional data were extracted
from external resources and integrated into KinMap.
Briefly: the number of kinase structures were obtained
from the Protein Data Bank [11], the number of assay and
compound values from ChEMBL [12], inhibition profiles
from published panels [4, 13], and information related to
kinase-disease associations from the Center for Thera-
peutic Target Validation (CTTV) platform [14]. The
current version of these data sources can be found online
at http://www.kinhub/kinmap/help-sources.html. In the
case of the CTTV data, entries with low association scores
(<0.1) were excluded, while only disease associations
linked to one or more of the following evidence types were
kept: genetic, somatic mutations, drugs, affected pathways
or RNA expression [14]. Eventually, this allows the user to
visually investigate kinase involvement in more than 670
diseases across 16 therapeutic areas.
A specialized navigation mode in KinMap allows inter-
active exploration of the relationships between these
data sources. Annotations can be added to the tree dir-
ectly from the built-in data sources, individually styled,
and interactively resized using relevant metrics such as
inhibition constants. Figure 1 outlines the key features of
KinMap and illustrates the combined annotations of the
inhibition profile of erlotinib [4] and kinases associated
with non-small cell lung carcinoma [14]. The annotated
tree in Fig. 1 exemplifies the identification of key targets,
e.g. EGFR and ABL1, responsible for the therapeutic ac-
tion of erlotinib.
Data input formats
In addition to the precompiled data sources, users
can create customized annotations in KinMap by
using various input formats ranging from a simple
list of kinases to complex spreadsheets and by
adjusting the styles, sizes, and text labels on the fly.
KinMap features an interactive spreadsheet editor
which enables the user to import annotations from
spreadsheets, to add or delete annotations, and to
modify annotations styles and sizes. Drop-down
menus with auto-complete functions increase the
convenience of adjusting annotations in the spread-
sheet editor. Moreover, KinMap can read additional
data from CSV input files, e.g. bioactivity values,
whereby the user can readjust annotation sizes using
the automated rescaling function in the spreadsheet
editor (Fig. 1c). Additional data can also serve as
information sources for the interactive kinome view
(discussed below). Finally, KinMap supports a mini-
malistic text input for less sophisticated annotations.
For example, the following concise syntax annotates eight
kinases potentially involved in cardiomyopathy [15]:
The first line defines the annotation style of the suc-
ceeding kinases until another assignment is specified. In
the present example, kinases are marked as squares that
are 25 × 25 pixels in size, colored in red, and surrounded
by a grey border.
Kinase names
Different naming schemes and abbreviations of ki-
nases are used by researchers across different groups
and/or disciplines. To account for this, KinMap con-
tains a versatile parsing function that links commonly
used kinase names to a unified naming scheme. The
current parsing function recognizes names used by
Manning [3], recommended by the UniProt Consor-
tium [16], approved by the HUGO Gene Nomencla-
ture Committee [17], as well as any of the alternative
names listed in these resources. Moreover, the parsing
function accepts incomplete or ambiguous kinase
names and allows the user to select the intended kin-
ase from a prioritized list of potential matches in a
specialized interface (Fig. 1d).
Visualization and interactive kinome view
KinMap can be used to produce sophisticated kinome
tree annotations integrating information from multiple
sources. The increasing availability and complexity of
kinase-related information can easily result in cluttered
kinome tree annotations that might be hard to grasp.
Therefore, we implemented additional visualization
options in KinMap to maximize the usability of the
annotated kinome tree, e.g. zoom and drag the view,
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customize text labels, and toggle tree components on
and off. In addition, KinMap introduces an interactive
mode providing a hovering function which can display
detailed information for a particular kinase such as
inhibition assay results (e.g. ABL1 in Fig. 1). The inter-
active view is particularly useful for browsing and shar-
ing complex data without overloading the information
content of the annotated kinome tree.
Fig. 1 The KinMap web interface. a Summary of the key features. b Navigation panel which allows linking kinome related data sources, e.g. non-
small cell lung carcinoma from CTTV (green triangles). c Preview of the built-in spreadsheet editor showing inhibition profile of erlotinib (red circles
on the tree) [4]; auto-complete functions (blue rectangles) facilitate kinase selection and style modification. Annotation sizes can be automatically
rescaled based on bioactivity data (red rectangles) or other input values in the spreadsheet. d Kinase name suggestions in case of incomplete or
ambiguous names in the input. e Supported output formats CSV: comma-separated values; PNG: Portable Network Graphics; SVG: Scalable Vector
Graphics; XML: extensible markup language; KMAP: native KinMap format. A box showing detailed information for the ABL1 kinase illustrates the
interactive view mode
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Output formats and data exchange
KinMap allows exporting annotated maps to static high-
quality images (PNG and SVG), e.g. for use in journal
publications and posters. Additionally, KinMap supports
three editable file formats: plain text (TXT), comma-
separated values (CSV), extensible markup language
(XML), and native KinMap (KMAP) format. The mini-
malistic plain text format (see example above) saves lists
of kinases and concise style directives making it suitable
for highlighting distinct subsets of kinases by different
annotation styles. The CSV format is more expansive
and can be modified using text editors or spreadsheet
software, e.g. Microsoft Excel, to facilitate data exchange.
Finally, the native KMAP format preserves the metadata
required to exactly reproduce the view of KinMap,
e.g. label font settings, zoom level, and interactive
mode settings.
Results and discussion
KinMap facilitates visualization of data from different re-
sources such as structural, biochemical, and functional
data, and allows not only generation of high-quality pic-
tures but also interactive exploration of connections.
The navigation possibilities will be now exemplarily
demonstrated in two test cases (Fig. 2). The first one
aims to identify new therapeutic applications for known
kinase inhibitors and the second one to prioritize kinases
for drug development projects. Instructions to produce
these illustrations are available in online tutorials at http://
www.kinhub/kinmap/tutorial.html and the corresponding
input files are provided in the Additional file 1.
Exploring novel therapeutic indications
Over the past few decades the development costs for
new drugs has increased dramatically, but this was para-
doxically accompanied by a decline in the likelihood of
approval in the clinical testing phases [18]. However,
clinically approved drugs and investigational drugs that
fail due to lack of efficacy or economic reasons could
still be leveraged to find new indications, a process re-
ferred to as drug repurposing. This approach is econom-
ically appealing as these drugs have already passed the
expensive early phases of clinical testing and have dem-
onstrated good safety profiles and, therefore, have lower
chances of subsequent clinical failure [19]. Exploring
novel indications is particularly valuable in the case of
anti-neoplastic kinase inhibitors due to the lower phase
1 success rate of oncology drugs (6.7%) compared to
other indications [18].
Figure 2a shows the inhibition profile of two clinically
approved kinase inhibitors, sorafenib and sunitinib,
against a panel of 317 protein kinases [4]. Sorafenib in-
hibits several tyrosine protein kinases, such as VEGFR,
PDGFR and Raf family kinases. It was initially approved
by the FDA for the treatment of patients with advanced
renal cancer in 2005 [20], and later also for hepatocellu-
lar carcinoma [21]. Sunitinib inhibits a number of recep-
tor tyrosine protein kinases including PDGFR (alpha and
beta), VEGFR2 (KDR), KIT, FLT3 and RET, which are
key factors in tumorigenesis and neoplastic cell prolifer-
ation [22]. In 2006, sunitinib was approved by the FDA
as a treatment for gastrointestinal stromal tumors and
renal carcinoma as well as for a rare type of pancreatic
Fig. 2 Examples of kinome tree annotation created by KinMap. a Inhibition profiles of two approved drugs sorafenib (orange circles) and sunitinib
(creme circles) [4], and kinases linked to thyroid carcinoma (blue squares) and colonic neoplasm (red squares) as extracted from the CTTV platform
[14]. b Availability of structural and bioactivity data for the human kinome; red circles: number of structures per kinase in the PDB [11]; blue circles:
number of activity measurements for the respective kinase in ChEMBL [12]; green triangles: key targets of clinically approved kinase inhibitors [12]
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cancer in 2011. Additionally, Fig. 2a shows the kinases
associated with two types of cancers for which both
drugs have not been initially approved: thyroid and
colon carcinomas [14]. The overlap between several key
targets of sorafenib and sunitinib, and kinases implicated
in thyroid and colon carcinomas indicates that the two
compounds are promising candidates for treatment of
both cancer types. Interestingly, a 2010 study of off-label
use of both drugs demonstrated the efficacy in patients
with widely metastatic, progressive differentiated thyroid
cancer [23]. Subsequently, sorafenib was approved by
the FDA for the treatment of metastatic differentiated
thyroid cancer in 2013, while sunitinib is currently in
phase 2 clinical trial as an adjunctive treatment for
advanced differentiated thyroid cancer [24]. Moreover,
off-label use of sorafenib showed positive results in per-
sonalized colon cancer therapy in a number of cases: e.g.
combining sorafenib with cetuximab and panitumumab
resulted in a notably long period of progression-free sur-
vival in a patient with V600E BRAF-mutant colon cancer
[25]. Furthermore, a metastatic colorectal cancer patient
with FLT3 mutation showed significant symptomatic
and laboratory improvement with sorafenib treatment
[26]. In line with these examples, KinMap facilitates
combining biochemical and disease pathology informa-
tion which can help uncover potential therapeutic indi-
cations of known kinase inhibitors.
Structure and bioactivity data
Current structural and biochemical coverage of the hu-
man kinome as well as the distribution of primary tar-
gets of clinically approved inhibitors are shown in
Fig. 2b, revealing some interesting insights. Firstly, most
of the kinases targeted by approved drugs (green trian-
gles) are located in the TK and TKL groups, leaving
ample therapeutic opportunities for drug development
against clinically relevant kinases in other groups. Sec-
ondly, nearly 200 kinases lack any experimental struc-
tures (red circles) in the PDB [11] despite having
abundant biochemical assay results (blue circles). For in-
stance, the dual specificity protein kinase CLK4 and the
RAC-gamma serine/threonine-protein kinase AKT3
have more than 2000 activity values in ChEMBL, but
lack PDB structures and were so far not considered as
key targets in drug development projects. Interestingly,
down-regulation of AKT3 was shown to inhibit tumor
growth in mouse xenograft models, providing a new
treatment option for the intractable triple-negative
breast cancer [27]. On the other hand, CLK4 plays a key
role in controlling the function of the spliceosome and
could be modulated to rectify splicing abnormalities in
several diseases including cancer [28]. Due to their po-
tential value in targeting oncogenesis [29], elucidating
their 3D structures would provide a competitive
advantage by guiding the rational development of novel
inhibitors. Finally, highlighting under-investigated ki-
nases can be combined with other kinome studies, e.g.
druggability assessment [6], to provide directions for fu-
ture drug development efforts.
Conclusions
Annotations of the phylogenetic tree of the human
kinome is an intuitive way to visualize and navigate
through the continuously growing knowledge in the pro-
tein kinase field such as the number of PDB structures,
compound data or kinase disease associations. The ana-
lysis options for the different data sources are manifold
and include keeping track of drug development projects,
repurposing clinically approved kinase inhibitors, or
uncovering potential new drug targets. KinMap facili-
tates such analysis by providing an interactive kinome
tree viewer that not only allows generating annotated
images and sharing data, but also provides a user-
friendly interface to explore data from different sources.
The key concepts of KinMap have been described here
along with two examples for using the navigation feature
to search for new therapeutic indications of two known
kinase inhibitors and to investigate the available struc-
tural and biochemical data on human kinases. We will
continually update the built-in resources and welcome
suggestions to integrate additional sources into KinMap.
Additional file
Additional file 1: (KinMap_Examples.zip) contains the input CSV files used
to generate the annotated kinome trees in Fig. 1 (Example_1_Erlotinib_
NSCLC.csv), Fig. 2a (Example_2_Sunitinib_Sorafenib_Cancer.csv), and Fig. 2b
(Example_3_Kinase_Stats.csv). (ZIP 5 kb)
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